Abstract
In recent years, the life expectancy of Multiple Myeloma (MM) patients has substantially improved, but this cancer remains incurable with increasing incidence in the developed world. Most MM patients will eventually relapse due to residual drug-resistant cancerous cells that survive treatment, commonly referred to as minimal residual disease (MRD). Methods to improve MRD detection in MM patients are generating considerable interest as a means of monitoring patients' response to treatment. In clinical laboratories, these methods currently require bone marrow aspirates which are invasive and frequently miss detection of localised disease due to the spatial heterogeneity of disease infiltration. By simplifying serial sampling and allowing for the detection of extramedullary disease, a blood-based method could significantly impact treatment duration and intensity and minimise chemotherapy-induced toxicity. This review will describe the current blood-based techniques available to detect MRD in MM and compare their potential to evaluate patient prognosis and drive therapeutic decisions.
Disciplines
Hematology | Oncology
DOI
10.1016/j.clml.2021.07.032
Full Publication Date
January 2022
Publisher
Elsevier
Resource Type
review article
Access Rights
open access
License Condition
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Aisling O'Brien, Fiona O'Halloran, Vitaliy Mykytiv, Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease, Clinical Lymphoma Myeloma and Leukemia, Volume 22, Issue 1, 2022. https://doi.org/10.1016/j.clml.2021.07.032
Publication Details
Clinical Lymphoma Myeloma and Leukemia